SCM
SGNT

Stevens Capital Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Stevens Capital Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-9,741
Closed -$245K – 1394
2014
Q4 		$245K Buy
+9,741
New +$286K 0.01% 793
2013
Q4 		– Sell
-9,997
Closed -$204K – 1378
2013
Q3 		$204K Buy
+9,997
New +$223K 0.01% 904

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stevens Capital Management's SGNT Position: Q1 2015 in Review

Stevens Capital Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q1 2015, closing a stake of 9,741 shares — an estimated $245K sold.

Stevens Capital Management first reported a position in SGNT in Q3 2013 and held it in 2 quarters. The position peaked at $245K in Q4 2014. 127 funds tracked by Wall St. Rank hold SGNT as of Q1 2015.

  • Stevens Capital Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Stevens Capital Management sold 9,741 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q1 2015, an estimated $245K.
  • Stevens Capital Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 2 quarters.
  • Stevens Capital Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $245K in Q4 2014.
  • 127 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q1 2015.

Based on Stevens Capital Management's 13F filing for Q1 2015, filed 7 May 2015.